8-K: FOXO Technologies CEO Reviews Strong 2025 Growth & Strategy

FOXO Technologies Inc. CEO Seamus Lagan provided a year-end review highlighting significant operational growth, strategic acquisitions, and financial improvements in 2025.

Summary

• FOXO Technologies Inc. acquired Myrtle Recovery Centers, Inc. and Rennova Community Health, Inc. (including Scott County Community Hospital) in mid-2024, and more recently Vector BioSource, Inc.
• Myrtle Recovery Centers' Oneida facility achieved a current average daily census of 28 (93% occupancy) in 2025, up from 7.4 (25% occupancy) in 2024, with projected patient admissions of 550 for 2025 compared to 195 in 2024.
• Scott County Community Hospital is projected to see over 7,000 ER patients, over 3,500 outpatient visits, and 300 inpatient stays in 2025, and recently added swing bed and wound care services.
• Vector BioSource, Inc. is expected to generate approximately $1 million in net revenues for 2025, with significant growth anticipated through capital investment and market expansion.
• The company reported net revenues of approximately $12 million for the nine months ended September 30, 2025, and expects to exceed $15 million for the full year ended December 31, 2025.
• Equity increased from $5.3 million at December 31, 2024, to $20.2 million at September 30, 2025, while debt was reduced from $10.2 million to $7.1 million over the same period.
• FOXO settled a $2.3 million legacy liability to Smithline and restructured approximately $3.5 million of legacy PIK note debt into preferred stock.
• The company formed FOXO Acquisition Corporation (FAC) and created Series E Cumulative Redeemable Secured Preferred Stock to facilitate future acquisitions.
• FOXO lost its NYSE American common stock listing in Q3 2025 due to minimum share price requirements and is considering options to uplist in 2026, though this is not certain.

Sentiment

Score: 7

Explanation: The filing presents strong operational growth, significant financial improvements (revenue, equity, debt reduction), and strategic acquisitions. However, the loss of the NYSE American listing and the uncertainty of future uplisting or preferred stock listing temper the overall positive sentiment.

Positives

• Myrtle Recovery Centers' Oneida facility achieved 93% occupancy (28 average daily census) in 2025, a significant increase from 25% (7.4 average daily census) in 2024.
• Projected patient admissions for Myrtle Recovery Centers increased substantially to 550 in 2025 from 195 in 2024.
• Myrtle Recovery Centers received funding through the State of Tennessee Opioid Abatement Fund for uninsured patients.
• Scott County Community Hospital expanded services by adding swing bed and wound care.
• The company projects net revenues to exceed $15 million for the full year 2025, up from approximately $12 million for the nine months ended September 30, 2025.
• Equity significantly strengthened, increasing from $5.3 million at December 31, 2024, to $20.2 million at September 30, 2025.
• Debt was reduced from $10.2 million at December 31, 2024, to $7.1 million at September 30, 2025.
• Legacy liabilities, including a $2.3 million liability to Smithline and $3.5 million of PIK note debt, were settled or restructured.

Negatives

• The company lost its NYSE American common stock listing in the third quarter of 2025 due to not meeting minimum share price requirements.

Risks

• Changes in the competitive and highly regulated industries in which FOXO operates.
• Variations in operating performance across competitors or changes in laws and regulations affecting FOXO's business.
• The ability to implement FOXO's business plans, forecasts, and other expectations.
• The ability to obtain financing.
• FOXO has a history of losses and may not achieve or maintain profitability in the future.
• The enforceability of FOXO's intellectual property, including its patents, and the potential infringement on the intellectual property rights of others.
• Downturns and a changing regulatory landscape in the highly competitive industries in which FOXO operates.
• Uncertainty regarding the eventual listing of the Series E Preferred Stock with its own trading symbol.
• No certainty of an eventual uplisting of common stock to NYSE American or another recognized stock exchange.

Future Outlook

The company remains optimistic about its operating subsidiaries and intends to augment organic growth with further acquisitions. It plans to invest capital in Vector BioSource for infrastructure, market expansion, and proprietary supply sources, expecting significant growth. FOXO also intends to list its Series E Preferred Stock, though this is not a certainty, and hopes to uplist its common stock to NYSE American or another recognized exchange in 2026, also without certainty.

Management Comments

• "We remain optimistic in our operating subsidiaries and are looking intently at augmenting organic growth with acquisitions."

Industry Context

FOXO Technologies is strategically expanding its footprint in the healthcare sector through acquisitions, focusing on substance use disorder treatment (Myrtle Recovery Centers), critical access hospital services (Scott County Community Hospital), and entering the pharmaceutical services sector with biospecimen sourcing (Vector BioSource). This diversification positions the company to capitalize on growing demand in behavioral health, rural healthcare, and the burgeoning biotech/pharma research market for biospecimens. The emphasis on acquisitions and operational improvements aligns with a broader trend of consolidation and specialization within the healthcare industry.

Comparison to Industry Standards

• NA

Corporate Governance

Stakeholder Impact

• Shareholders: Potential for increased value from operational growth and acquisitions, but also risk from common stock delisting and uncertainty of uplisting. Preferred shareholders benefit from secured dividends.
• Patients: Improved access to substance use disorder treatment and critical access hospital services, with new after-care support via the Evana app.
• Employees: Potential for growth and expansion in healthcare and pharmaceutical services segments.
• Biotechnology and Pharmaceutical Research Sectors: Benefit from Vector BioSource's expanded biospecimen sourcing capabilities.

Next Steps

• Myrtle Recovery Centers is actively considering other locations to replicate its operating model due to consistent capacity and excess referrals.
• Myrtle is working with software developers on a mobile application called Evana to connect post-discharge patients with care professionals.
• FOXO plans to invest capital in Vector BioSource to build infrastructure, expand markets, and secure proprietary sources of supply.
• The company intends to list its Series E Preferred Stock with its own trading symbol, though this is not a certainty.
• FOXO continues to consider options to uplist its common stock to NYSE American or another recognized stock exchange, hoping to achieve this in 2026.

Key Dates

Recommendation

The company demonstrates strong operational improvements, significant revenue growth, and a strengthened balance sheet through debt reduction and equity increase. Strategic acquisitions are expanding its market presence in growing healthcare sectors. However, the loss of the NYSE American listing and the uncertainty surrounding future uplisting and preferred stock listing introduce considerable risk and liquidity concerns for common shareholders. While the underlying business performance is positive, the current OTC listing status and future listing uncertainties warrant a 'hold' recommendation for a seasoned investor, suggesting observation of uplisting progress before a more aggressive stance.

Keywords

Healthcare, Substance Use Disorder Treatment, Hospital, Biospecimens, Pharmaceutical Services, Biotechnology, Acquisitions, Financial Performance, Debt Reduction, Equity Growth, Preferred Stock, Uplisting